OCULAR THERAPEUTIX, INC (OCUL) has 5 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 5 sales totalling $333K. Most recent filing: Sept. 2, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 2, 2026 filed Aug. 31, 2026 | Notman Donald Chief Operating Officer | −$11,254 | 1,099 | −0% | No | |
|
|
||||||
| Aug. 26, 2026 filed Aug. 24, 2026 | Kaiser Peter Chief Development Officer | −$32,687 | 3,035 | −1% | Yes | |
|
|
||||||
| Aug. 26, 2026 filed Aug. 24, 2026 | Nayak Sanjay Chief Strategy Officer | −$20,450 | 1,897 | −1% | Yes | |
|
|
||||||
| Aug. 26, 2026 filed Aug. 24, 2026 | Heier Jeffrey S. Chief Scientific Officer | −$35,531 | 3,296 | −1% | Yes | |
|
|
||||||
| Aug. 26, 2026 filed Aug. 24, 2026 | Dugel Pravin See Remarks | −$70,360 | 121,833 | −3% | Yes | |
|
|
||||||
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free